Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Post-delivery withdrawal time of tenofovir for blocking mother-to-child transmission of HBV in women with high HBV load during late pregnancy

Na Bai, Yingmei Zhang, Ming Yang, Yuan Gao, Ruijia Yang, Chunyan Zhu, Yunhui Bai , Wei Shi

Department of Clinical Laboratory, Southern Central Hospital of Yunnan Province (The First People’s Hospital of Honghe State), Mengzi, China;

For correspondence:- Yunhui Bai Email: baiyunhui100@126.com

Accepted: 01 November 2023 Published: 30 November 2023

Citation: Bai N, Zhang Y, Yang M, Gao Y, Yang R, Zhu C, et al. Post-delivery withdrawal time of tenofovir for blocking mother-to-child transmission of HBV in women with high HBV load during late pregnancy. Trop J Pharm Res 2023; 22(11):2333-2339 doi: 10.4314/tjpr.v22i11.13

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the withdrawal time of tenofovir disoproxil fumarate (TDF) after delivery in parturient women having high hepatitis B virus (HBV) load who took TDF during late pregnancy to block fetal contact with HBV.

Methods: This is a retrospective analysis of clinical data of 77 pregnant women close to parturition with high HBV density in Southern Central Hospital of Yunan Province from February 2020 to February 2021. Based on time of drug discontinuation, they were assigned to group A (immediately after delivery, n = 24); group B (1 month after delivery, n = 26), and group C (3 months after delivery, n = 27). All three groups took TDF before delivery. Liver function, with alanine aminotransferase (ALT) was assessed using Roche detection system. Deoxyribonucleic acid of hepatitis B virus (HBV-DNA) was assayed by fluorescence quantitative method. Hepatitis B surface antigen (HBsAg) and HB e antigen (HBeAg) were measured using chemiluminescence microparticle immunoassay (CMIA). All assays were done after 2, 4, 8, 12, 18 and 24 weeks of drug withdrawal.

Results: All parameters in the three groups of patients returned to normal levels after 2, 4, 8, 12, 18 and 24 weeks of drug withdrawal. In 83 neonates, tests for hepatitis B DNA and surface antigen were negative 1 month after birth, with 100 % block of maternal neonatal transmission, and no HBV infection. The incidence of adverse reactions in pregnant women were 16.67, 19.24 and 18.52 % in groups A, B and C, respectively, with no significant difference (p > 0.05).

Conclusion: The therapeutic effect of TDF for parturient women with high HBV density is not related to drug withdrawal time after delivery. It is necessary to increase the number of samples in subsequent studies in order to validate the research results.

Keywords: High hepatitis B virus (HBV) load, Late pregnancy, Tenofovir disoproxil fumarate (TDF), Blocking mother-to-child transmission of HBV, Withdrawal time